Adviser Investments LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Adviser Investments LLC grew its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 5.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,899 shares of the company’s stock after purchasing an additional 3,750 shares during the quarter. Johnson & Johnson makes up about 0.9% of Adviser Investments LLC’s portfolio, making the stock its 24th biggest holding. Adviser Investments LLC’s holdings in Johnson & Johnson were worth $13,983,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. State Street Corp grew its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after buying an additional 1,084,834 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $4,172,929,000. Finally, Legal & General Group Plc boosted its position in shares of Johnson & Johnson by 5.8% during the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after acquiring an additional 948,306 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. SVB Leerink cut their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Raymond James lifted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Trading Down 1.6 %

Shares of JNJ stock opened at $171.79 on Friday. The company has a 50 day moving average of $175.41 and a 200-day moving average of $174.52. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The firm has a market cap of $451.67 billion, a P/E ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.48 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.